BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
BioNexus Gene Lab's price to book ratio was 0.3× on Nov 11, 2026, against 1.2× a year earlier. Over the last 4 years it ranged from 0.3× to 270.3×, with a median of 7.8×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.3× | −0.8 |
| 2025 | Dec 31, 2025 | 1.0× | −4.3 |
| 2024 | Dec 31, 2024 | 5.4× | −4.8 |
| 2023 | Dec 29, 2023 | 10.1× | −89.3 |
| 2020 | Aug 31, 2020 | 99.4× | – |
See a number that looks wrong?